-
Senators to FDA: Take action on proliferation of social media drug ads
Senators are urging the FDA to update decade-old guidance and take action to rein in social media advertisements of prescription drugs from telehealth companies, requesting that the agency respond to their concerns by March 27, according to a Feb. 15 Wall Street Journal report. -
FTC probes whether GPOs, wholesalers cause drug shortages
The Federal Trade Commission and HHS launched an investigation Feb. 14 into how group purchasing organizations and drug wholesalers might cause drug shortages. -
Mark Cuban drug company unveils new offering for hospitals
Mark Cuban Cost Plus Drug Co. now offers critical drugs in shortage to healthcare providers. -
Harvard gets $1.2M to develop oral antibiotics that kill drug-resistant infections
Harvard University researchers have received $1.2 million from CARB-X, a Boston University-led nonprofit that funds projects that focus on drug-resistant bacteria named on the CDC’s Antibiotic Resistant Threats list. -
FDA sends warning letters to vendors selling unapproved weight loss drugs
The FDA has sent warning letters to two online vendors — US Chem Labs and Helix Chemical Supply — for selling unapproved and misbranded versions of semaglutide and tirzepatide. -
FDA approves 1st treatment for severe frostbite
On Feb. 14, the FDA approved Aurlumyn, the nation's first treatment for severe frostbite. -
Discontinued asthma drug stirs frustrations
After GSK discontinued its brand-name asthma drug Flovent on Jan. 1, families and physicians are struggling to access its generic solution, CNN reported Feb. 13. -
6 Ozempic updates
Healthcare suppliers and food companies are veering into new business plans amid the booming market for weight loss medications, which is expected to reach $80 billion by 2030. -
FDA clears drug for metastatic pancreatic cancer
The FDA has granted approval to a new medicine for patients with aggressive, metastatic pancreatic adenocarcinoma. The agency began its priority review of the drug following positive phase 3 trial results. -
Gilead scoops drugmaker for $4.3B
Gilead Sciences bought a liver disease drugmaker Feb. 12 for $4.3 billion. -
Ebola vaccine cuts death risk for people with past infections
Ervebo, Merck's Ebola vaccine, reduced the fatality risk among patients who previously contracted the rare disease that kills 50% of those affected, according to new research. -
UT Southwestern partners with Pfizer on RNA delivery tech
Dallas-based UT Southwestern Medical Center is partnering with Pfizer to develop RNA-enhanced delivery technologies for genetic medicine therapies. -
2M lab devices flagged for testing issue
More than 2 million 2,363,168 products BD Sensi-Disc products cannot be used for Haemophilus influenzae testing, a Becton Dickinson spokesperson told Becker's. -
CDC seeks to expand U of Michigan's hypertension pharmacy program model
The University of Michigan in Ann Arbor has piloted a program aimed at involving pharmacists as part of the care team for patients with hypertension. Its success has prompted the CDC to begin scaling the model for wider use. -
This cancer drug could treat Parkinson's
A chemotherapy drug could potentially be a treatment for Parkinson's disease, a recent study found. -
Gyms, nutrition startups race to combat Ozempic muscle loss
A growing number of companies ranging from gyms to meal delivery services are launching new offerings to capitalize on a known issue that can happen for patients on weight loss drugs such as Ozempic and Wegovy, The New York Times reported Feb. 8. -
Ohio fines 1 CVS store $250K for understaffing
Ohio's Board of Pharmacy handed a CVS pharmacy a $250,000 fine and probation for at least three years following a 2021 investigation that found understaffing, a broken air conditioning unit, unsafe storage for medications and other issues. -
If FDA swipes common decongestant, supply issues expected
If the FDA removes the approval of phenylephrine, a common ingredient used in decongestants that research shows is ineffective, a new study says supply chain disruptions are likely. -
Aspiring pharmacist union slams CVS' $2B earnings
A day after CVS Health reported earning $2 billion in its fourth quarter of 2023, the Pharmacy Guild — an aspiring union of retail pharmacists — criticized the company, saying CVS' profits are from "chronic understaffing." -
HHS to pharmacies: Ensure patients aren't overcharged for Paxlovid
In a Feb. 5 meeting with retail pharmacy CEOs, HHS Secretary Xavier Becerra stressed that patients should not be paying the full list price or high copays for Pfizer's Paxlovid drug.
Page 23 of 50